Who owns Mereo Biopharma Group Plc ads?
- Ticker: MREO
- CUSIP Number: 589492107
Tip: Access positions for across all investors
Analyze quarterly positions in Mereo Biopharma Group Plc ads with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Mereo Biopharma Group Plc ads stock
Who bought or sold Mereo Biopharma Group Plc ads this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Rubric Capital Management | 14M | $45M | 17% | Mar 2024 |
|
| Adage Capital Partners GP | 9.3M | $31M | 1066% | Mar 2024 |
|
| Mangrove Partners | 8.8M | $29M | 58% | Mar 2024 |
|
| Rock Springs Capital Management | 8.1M | $27M | 6% | Mar 2024 |
|
| 683 Capital Management | 5.8M | $19M | -7% | Mar 2024 |
|
| Henderson Group | 5.1M | $17M | 100% | Mar 2024 |
|
| Suvretta Capital Management | 3.7M | $12M | -50% | Mar 2024 |
|
| Clearline Capital | 3.3M | $11M | 0% | Mar 2024 |
|
| Soleus Capital Management | 2.6M | $8.6M | -73% | Mar 2024 |
|
| Tejara Capital | 2.5M | $8.2M | -33% | Mar 2024 |
|
| Goldman Sachs Group | 2.2M | $7.4M | 11% | Mar 2024 |
|
| Millennium Management | 2.2M | $7.2M | 55% | Mar 2024 |
|
| Susquehanna International | 1.9M | $6.3M | 770% | Mar 2024 |
|
| Morgan Stanley | 1.4M | $4.6M | 20559% | Mar 2024 |
|
| T. Rowe Price Associates | 992k | $3.3M | 100% | Mar 2024 |
|
| Integral Health Asset Management | 950k | $3.1M | 100% | Mar 2024 |
|
| Standard Life Aberdeen | 817k | $2.7M | -47% | Mar 2024 |
|
| NEOS Investment Management | 623k | $2.1M | 1408% | Mar 2024 |
|
| Verition Fund Management | 485k | $1.6M | 100% | Mar 2024 |
|
| Artia Global Partners | 421k | $1.4M | 100% | Mar 2024 |
|
| Monaco Asset Management SAM | 405k | $1.3M | -40% | Mar 2024 |
|
| Two Sigma Investments | 352k | $1.2M | 13% | Mar 2024 |
|
| J. Goldman & Co | 279k | $919k | 72% | Mar 2024 |
|
| Knoll Capital Management | 261k | $860k | 62% | Mar 2024 |
|
| EAM Global Investors | 195k | $644k | 100% | Mar 2024 |
|
| Fred Alger Management | 195k | $643k | 90% | Mar 2024 |
|
| Citadel Advisors | 149k | $493k | -57% | Mar 2024 |
|
| TD Asset Management | 148k | $488k | 100% | Mar 2024 |
|
| Qube Research & Technologies | 109k | $361k | 100% | Mar 2024 |
|
| Geode Capital Management | 97k | $319k | 0% | Mar 2024 |
|
| Jane Street | 87k | $287k | 100% | Mar 2024 |
|
| Bank of America Corporation | 79k | $260k | 28421% | Mar 2024 |
|
| GSA Capital Partners | 76k | $250k | 100% | Mar 2024 |
|
| Hsbc Holdings | 58k | $135k | 0% | Dec 2023 |
|
| Gts Securities | 58k | $190k | 100% | Mar 2024 |
|
| Envestnet Asset Management | 56k | $185k | 100% | Mar 2024 |
|
| PRIMECAP Management Company | 54k | $125k | -32% | Dec 2023 |
|
| Squarepoint Ops | 48k | $157k | -81% | Mar 2024 |
|
| Cubist Systematic Strategies | 47k | $155k | 220% | Mar 2024 |
|
| Clear Harbor Asset Management | 46k | $152k | -23% | Mar 2024 |
|
| Forefront Analytics | 44k | $145k | -33% | Mar 2024 |
|
| Jpmorgan Chase & Co | 38k | $126k | 99% | Mar 2024 |
|
| BlackRock | 33k | $108k | 100% | Mar 2024 |
|
| PFG Investments | 31k | $103k | 4% | Mar 2024 |
|
| Index Fund Advisors | 30k | $99k | 100% | Mar 2024 |
|
| Simplex Trading | 29k | $96k | 100% | Mar 2024 |
|
| Tudor Investment Corporation | 26k | $86k | 100% | Mar 2024 |
|
| Centiva Capital | 25k | $83k | 0% | Mar 2024 |
|
| Virtu Financial | 20k | $47k | -40% | Dec 2023 |
|
| Golden State Equity Partners | 20k | $47k | 41% | Dec 2023 |
|
| Level Four Advisory Services | 20k | $46k | 0% | Mar 2024 |
|
| Resources Investment Advisors | 19k | $61k | -30% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 17k | $58k | 581067% | Mar 2024 |
|
| SG Americas Securities | 16k | $54k | 100% | Mar 2024 |
|
| Total Clarity Wealth Management | 12k | $39k | 100% | Mar 2024 |
|
| Newbridge Financial Services Group | 12k | $39k | 23% | Mar 2024 |
|
| Advisors Preferred | 8.3k | $28k | 100% | Mar 2024 |
|
| Tower Research Capital | 7.1k | $24k | 100% | Mar 2024 |
|
| GAMMA Investing | 6.0k | $20k | 30% | Mar 2024 |
|
| Rhumbline Advisers | 4.1k | $13k | 4% | Mar 2024 |
|
| SRS Capital Advisors | 4.0k | $9.2k | 0% | Dec 2023 |
|
| Lindbrook Capital | 2.3k | $7.6k | 100% | Mar 2024 |
|
| Point72 Asset Management | 1.9k | $6.3k | 100% | Mar 2024 |
|
| Hanson McClain Advisors | 1.5k | $5.0k | 0% | Mar 2024 |
|
| BFSG | 1.0k | $3.3k | 100% | Mar 2024 |
|
| ICA Group Wealth Management | 1.0k | $3.3k | 100% | Mar 2024 |
|
| Sit Investment Associates | 970.00 | $3.0k | 0% | Mar 2024 |
|
| Signature | 820.00 | $2.7k | 100% | Mar 2024 |
|
| Quadrant Capital | 739.00 | $2.4k | 100% | Mar 2024 |
|
| Us Bancorp | 413.00 | $1.4k | 3077% | Mar 2024 |
|
| New England Capital Financial Advisors | 300.00 | $990.000000 | 0% | Mar 2024 |
|
| Wells Fargo & Company | 230.00 | $756.999000 | 0% | Mar 2024 |
|
| Highlander Capital Management | 127.00 | $293.001700 | 0% | Dec 2023 |
|
| Plante Moran Financial Advisors | 48.00 | $158.001600 | 0% | Mar 2024 |
|
| Barclays | 38.00 | $0 | 0% | Mar 2024 |
|
| Royal Bank of Canada | 28.00 | $0 | -51% | Mar 2024 |
|
Who sold out of Mereo Biopharma Group Plc ads?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| DAFNA Capital Management | Dec 2023 | 779k | $1.8M |
| Toroso Investments | Dec 2023 | 319k | $738k |
| Boothbay Fund Management | Sep 2023 | 121k | $156k |
| Schonfeld Strategic Advisors | Dec 2023 | 50k | $116k |
| Lynwood Capital Management | Dec 2023 | 25k | $58k |
| Privium Fund Management | Sep 2023 | 25k | $32k |
| Marshall Wace | Dec 2023 | 15k | $34k |
| Oppenheimer & Co | Sep 2023 | 14k | $18k |
| XTX Topco | Sep 2023 | 11k | $15k |
| UBS Group | Dec 2023 | 2.8k | $6.5k |
| Spire Wealth Management | Dec 2023 | 250.00 | $789.000000 |